Novo Nordisk eyes long-term weight loss with new GLP-1 implant

The experimental implant, designated NPM-139, aims to transform weight maintenance into a semi-annual or even annual procedure. Vivani proposes that patients reach their target dose through traditional injections or pills before transitioning to the implant for sustained care. CEO Adam Mendelsohn argues that this approach could mitigate the discontinuation rates currently hindering the full medical potential of existing therapies.

Despite the partnership, the technology faces a long path to clinical adoption. Experts remain cautious, noting that the device must still navigate rigorous trials and prove its efficacy against established market leaders. Dr. Miranda Stiewig-Rapp of UC Davis Health emphasized that while the concept of a long-term delivery system is appealing, physicians require concrete data on patient tolerance and real-world outcomes before broad implementation. Furthermore, the financial landscape remains opaque, as neither the manufacturing costs nor the potential for insurance coverage have been established in a sector projected to hit $100 billion by the early 2030s.